Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes

Diabetes

Volumn 57, Issue 1, 2008, Pages 24-31

  Basu, Rita ^a   Shah, Pankaj ^b   Basu, Ananda ^a   Norby, Barbara ^a   Dicke, Betty ^a   Chandramouli, Visvanathan ^c   Cohen, Ohad ^d   Landau, Bernard R ^c   Rizza, Robert A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; FATTY ACID; GLUCAGON; INSULIN; METFORMIN; PIOGLITAZONE; SOMATOSTATIN; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCEROL; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MECHANISM; FEMALE; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORT; GLYCOGENOLYSIS; HORMONE ACTION; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; BLOOD; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC DIET; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; LIVER; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCAGON; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLYCEROL; GLYCOGENOLYSIS; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; KINETICS; LIVER; MALE; METFORMIN; MIDDLE AGED; PLACEBOS; THIAZOLIDINEDIONES;

EID: 38449086259     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-0827     Document Type: Article

References (49)

1. Buse JB, Polonsky KS, Burant CF: Chapter 29: Type 2 Diabetes Mellitus. In Larsen:Williams Textbook of Endocrinology, 10th ed. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, Eds. Philadelphia, PA, Saunders, 2003, p. 1427-1482
2. Sherwin RS: Chapter 242: Diabetes Mellitus. In Cecil Textbook of Medicine, 22nd ed. Goldman L, Ausiello D, Eds. Philadelphia, PA, Saunders, 2004, p. 1424-1452
3. Kerpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 137:25-33, 2002
4. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360-372, 2002
5. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349, 2002
6. Kobayashi M, Iwanishi M, Egawa K, Shigeta Y: Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 41:476-483, 1992
7. Fryer LGD, Parbu-Patel A, Carling D: The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277:25226-25232, 2002
8. Ciaraldi TP, Kong APS, Chu NV, Kim DD, Basxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR: Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 51:30-36, 2002
9. Fulgencio J-P, Kohn C, Girard J, Pégorier J-P: Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45:1556-1562, 1996
10. Wollen N, Bailey CJ: Inhibition of hepatic gluconeogenesis by metformin: synergism with insulin. Biochem Pharmacol 37:4353-4358, 1988
11. Matthaei S, Hamann A, Klein HH, Benecke H, Kreymann G, Flier JS, Greten H: Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation pool to plasma membrane in rat adipocytes. Diabetes 40:850-857, 1991
12. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
13. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069, 2000
14. Gastaldelli A, Miyazaki Y, Pettiti M, Santini E, Ciociaro D, DeFronzo RA, Ferrannini E: The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. J Clin Endocrinol Metab 91:806-812, 2006
15. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
16. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M: Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53:1621-1629, 2004
17. Natali A, Ferrannini E: Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49:434-441, 2006
18. DeFronzo RA, Barzilai N, Simonson DC: Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 73:1294-1301, 1991
19. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O: Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh) 120:257-265, 1989
20. Nosadini R, Avogaro A, Trevisan R, Valerio A, Tessari P, Duner E, Tiengo A, Velussi M, Del Prato S, De Kreutzenberg S, Muggeo M, Crepaldi G: Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptor in type II diabetes. Diabetes Care 10:62-67, 1987
21. Johnson AB, Webster JM, Sum C-F, Heseltine L, Argyraki M, Cooper BG, Taylor R: The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 42:1217-1222, 1993
22. Fendri S, Debussche X, Puy H, Vincent O, Marcelli JM, Dubreuil A, Lalau JD: Metformin effects on peripheral sensitivity to insulin in non diabetic obese subjects. Diabete Metab 19:245-249, 1993
23. Karlsson HK, Haalsten K, Bjornholm M, Tsuchida H, Chibalin AV, Virtanen KA, Heinonen OJ, Lonnqvist F, Nuutila P, Zierath JR: Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes 54:1459-1467, 2005
24. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MG: Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 88:1637-1645, 2003
25. Hallsten K, Virtanen KA, Lonnqvist F, Sipila H, Oksanen A, Viljanen T, Ronnemaa T, Viikari J, Knuuti J, Nuutila P: Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479-3485, 2002
26. Firth RG, Bell PM, Rizza RA: Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 314:1280-1286, 1986
27. Simonson DC, Ferrannini E, Bevilacqua S, Smith D, Barrett E, Carlson R, DeFronzo RA: Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 33:838-845, 1984
28. Yki-Jarvinen H, Helve E, Koivisto VA: Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes 36:892-896, 1987
29. Miyazaki Y, Mahankali A, Matsuda M, Mahankalo S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791, 2002
30. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719, 2001
31. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219, 2001
32. Tiikkainen M, Hakkinen A-M, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176, 2004
33. Rizza RA, Mandarino LJ, Gerich JE: Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240:E630-E639, 1981
34. Miles J, Glasscock R, Aikens J, Gerich J, Haymond M: A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res 24:96-99, 1983
35. 2O administration. Anal Biochem 297:195-197, 2001
36. Jensen MD, Kanaley JA, Reed JE, Sheedy PF: Measurement of abdominal and visceral fat with computed tomography and dual-energy x-ray absorptiometry. Am J Clin Nutr 61:274-278, 1995
37. Steele R, Wall J, DeBodo R, Altszuler N: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15-24, 1956
38. Basu R, Chandramouli V, Dicke B, Landau B, Rizza R: Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes 54:1942-1948, 2005
39. Fruehwald-Schultes B, Oltmanns KM, Toschek B, Sopke S, Kern W, Born J, Fehn HL, Peters A: Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism 51:531-536, 2002
40. Baptista T, Sandia I, Lacruz A, Rangel N, de Mendoza S, Beaulieu S, Contreras Q, Galeazzi T, Vargas D: Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 22:69-76, 2007
41. Cunha MR, da Silva ME, Machado HA, Fukui RT, Correa MR, Santos RF, Wajchenberg BL, Rondon MU, Negrao CE, Ursich MJ: The effects of metformin and glibenclamide on glucose metabolism, counter-regulatory hormones and cardiovascular responses in women with type 2 diabetes during exercise of moderate intensity. Diabet Med 24:592-599 2007
42. Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA: The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 29:2275-2281, 2006
43. Phillips SA, Ciaraldi TP, Kong APS, Bandukwala R, Aroda V, Carter L, Baxi S, Maduliar SR, Henry RR: Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52:667-674, 2003
44. Boden G, Chen X, Capulong E, Mozzoli M: Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 50:810-816, 2001
45. Chen X, Iqbal N, Boden G: The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 103:365-372, 1999
46. Ye J-M, Dzamko N, Cleasby ME, Hegarty BD, Furler SM, Cooney GJ, Kraegen EW: Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 47:1306-1313, 2004
47. Garber AL, Duncan TG, Goodman AM, Mills DJ, Rohlf JL: Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 102:491-497, 1997
48. Yki-Jarvinen H: Glucose toxicity. Endocr Rev 13:415-431, 1992
49. Kahn MA, St. Peter JV, Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25:708-711, 2002